IP Library › Granted Patent US 12,083,232
Granted Patent B2
US 12,083,232 · App. 16/630,402 · Granted Sep 10, 2024

Wound care materials, devices and uses

Inventors: Anthony Dagger (York, GB); Helene Anne Lecomte (York, GB)
Assignee: Smith & Nephew PLC
A61L15/225A61F13/00063A61F13/01012A61F13/01017A61F13/01042A61F13/05A61L15/18A61L15/26A61L15/28A61L15/46A61L15/60A61F13/0209A61L2300/102A61L2300/104A61L2300/108A61L2300/404A61M1/79
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,083,232
App. No.
16/630,402
Granted
Sep 10, 2024
Kind
B2
Abstract

Material comprising a flexible porous hydrophilic polymer foam or fibre matrix comprising two matrix faces and therebetween a structural matrix framework defining a network of cells, having a cell network surface and therein a network of pores and a powder charge comprising antimicrobial additive and/or wound dressing additive, wherein the powder charge is comprised at the matrix face or faces and/or within the cell network or within the structural matrix framework and wherein the additive is micronized, a method for the preparation thereof comprising micronizing the additive and dosing powder charge to the matrix or a reactive phase for the manufacture of said matrix, devices comprising the material and uses thereof.

Claims (28)

1. Material comprising a flexible porous hydrophilic polymer foam or fibre matrix comprising two matrix faces and therebetween a structural matrix framework defining a network of cells, having a cell network surface and therein a network of pores and

a powder charge comprising an antimicrobial additive,

wherein said powder charge is comprised at said matrix face or faces and/or within said cell network or within said structural matrix framework

and wherein the additive is micronized,

wherein the micronized additive has loss on drying (L.O.D) less than 2% and/or

said powder charge additionally comprises flowing agent and/or bulking agent wherein micronized additive is co-located with said flowing agent and/or bulking agent;

wherein the antimicrobial additive comprises silver salt.

2. A wound dressing, comprising:

a loaded wound dressing layer comprising:

a porous polymer foam matrix comprising a wound facing face and a reverse face; and

a powder charge of micronized antimicrobial release additive loaded within the matrix;

wherein the antimicrobial release additive comprises silver salt;

wherein the antimicrobial release additive has a particle size distribution of 1 micron<D50<30 micron.

3. The wound dressing of claim 2 , wherein the matrix comprises a polyurethane polymer foam.

4. The wound dressing of claim 2 , wherein the matrix comprises a fibrous matrix.

5. The wound dressing of claim 2 , wherein the matrix comprises a hydrophilic polymer.

6. The wound dressing of claim 2 , wherein the micronized antimicrobial release additive has L.O.D. (Loss on Drying)<2 wt %, wherein L.O.D. is established by drying a sample thereof during 4 hours in vacuum oven at 50° C. or in non-vacuum oven at 105° C.

7. The wound dressing of claim 2 , wherein the micronized antimicrobial release additive is formed by dry micronization with use of milling media selected from gaseous milling media and particulate milling media.

8. The wound dressing of claim 2 , wherein the powder charge of micronized antimicrobial release additive further comprises a flowing agent selected from a group consisting of stearate salt, clay, silica, charcoal, graphite and a combination thereof.

9. The wound dressing of claim 2 , wherein the powder charge of micronized antimicrobial release additive further comprises a bulking agent selected from a group consisting of PEG, PVP, sodium polyacrylate, cross linked carboxymethyl cellulose (CMC or other absorbent functionalised (by carboxylation or sulfonation) cellulose derivatives), cross linked polyethylene oxide and PVA copolymer.

10. The wound dressing of claim 2 , wherein the antimicrobial release additive is selected from a group consisting of silver sulfadiazine, silver zeolite, silver sulfate, silver carbonate, silver chloride, silver nitrate, silver oxide, silver phosphate, silver citrate, silver acetate, silver lactate, and combinations thereof.

11. The wound dressing of claim 2 , wherein the powder charge of micronized antimicrobial release additive further comprises super absorbent polymer.

12. The wound dressing of claim 2 , wherein the antimicrobial release additive is in an amount of 1.4 mg/cm 2 to 4 mg/cm 2 at the wound facing face.

13. The wound dressing of claim 2 , further comprising a wound contact layer below the loaded wound dressing layer.

14. The wound dressing of claim 2 , further comprising a cover layer over the loaded wound dressing layer.

15. The wound dressing of claim 14 , further comprising a fluidic connector configured to connect the cover layer to a source of negative pressure.

16. The wound dressing of claim 2 , further comprising an absorbent layer over the loaded wound dressing layer, wherein the absorbent layer comprises superabsorbent particles.

17. The wound dressing of claim 2 , wherein the matrix comprises a plurality of cells and wherein the antimicrobial release additive is at least partially embedded within said cells.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 23, 2020
From: DAGGER, ANTHONY; LECOMTE, HELENE ANNE
To: T.J.SMITH AND NEPHEW,LIMITED
Reel/Frame 054741/0938 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 23, 2020
From: T.J.SMITH AND NEPHEW,LIMITED
To: SMITH & NEPHEW PLC
Reel/Frame 054742/0001 →
Priority Claims (1)
GB 1711179 · Jul 12, 2017 · national
Continuity (1)
Related Publication 20210146000A1 · May 20, 2021